EirGenix Inc. (TPE:6589)
Taiwan · Delayed Price · Currency is TWD 42.15
+0.65 (1.57%)
At close: May 29, 2026
EirGenix Revenue
EirGenix had revenue of 308.44M TWD in the quarter ending March 31, 2026, with 69.54% growth. This brings the company's revenue in the last twelve months to 1.13B, up 16.52% year-over-year. In the year 2025, EirGenix had annual revenue of 1.01B, down -0.38%.
Revenue (ttm)
1.13B
Revenue Growth
+16.52%
P/S Ratio
11.27
Revenue / Employee
1.13M
Employees
1,000
Market Cap
12.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.01B | -3.80M | -0.38% |
| Dec 31, 2024 | 1.01B | -13.69M | -1.34% |
| Dec 31, 2023 | 1.02B | -458.36M | -30.95% |
| Dec 31, 2022 | 1.48B | -216.34M | -12.75% |
| Dec 31, 2021 | 1.70B | 625.52M | 58.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.04B |
| Ever Supreme Bio Technology | 1.03B |
| PharmaEngine | 963.83M |
| Medigen Vaccine Biologics | 603.68M |
| TaiMed Biologics | 601.19M |
| Tanvex BioPharma | 483.94M |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |